OBJECTIVES: To ascertain attitudes of prospective patients relevant to the delivery of race-based pharmacogenomics. METHODS: Written anonymous survey and qualitative responses in two sets of reactance format focus groups over-sampled for minority groups in urban, suburban, and rural communities conducted from February through April, 2002 [N = 104] and August through November, 2002 [N = 120]. RESULTS: Participants do not associate "races" exclusively with continental clusters. They have incomplete knowledge of their recent ancestors (39.6% do not know all their biological grandparents). They would be highly suspicious of race-labeled drugs; with 47.5% saying they would be very suspicious of their safety and 40.6% indicating they would be very suspicious of their efficacy. A substantial minority of African-American participants (13.2%) would prefer to take the drugs designated for European Americans. Effect of discussion of race-based medicine on racial attitudes is ambiguous. CONCLUSIONS: Patient knowledge of ancestry and suspicion of race-designated drugs constitute substantial barriers that need to be incorporated in judging the likely effectiveness of race-based pharmacogenomics.
OBJECTIVES: To ascertain attitudes of prospective patients relevant to the delivery of race-based pharmacogenomics. METHODS: Written anonymous survey and qualitative responses in two sets of reactance format focus groups over-sampled for minority groups in urban, suburban, and rural communities conducted from February through April, 2002 [N = 104] and August through November, 2002 [N = 120]. RESULTS:Participants do not associate "races" exclusively with continental clusters. They have incomplete knowledge of their recent ancestors (39.6% do not know all their biological grandparents). They would be highly suspicious of race-labeled drugs; with 47.5% saying they would be very suspicious of their safety and 40.6% indicating they would be very suspicious of their efficacy. A substantial minority of African-American participants (13.2%) would prefer to take the drugs designated for European Americans. Effect of discussion of race-based medicine on racial attitudes is ambiguous. CONCLUSIONS:Patient knowledge of ancestry and suspicion of race-designated drugs constitute substantial barriers that need to be incorporated in judging the likely effectiveness of race-based pharmacogenomics.
Entities:
Keywords:
Empirical Approach; Genetics and Reproduction
Authors: Pamela Sankar; Mildred K Cho; Celeste M Condit; Linda M Hunt; Barbara Koenig; Patricia Marshall; Sandra Soo-Jin Lee; Paul Spicer Journal: JAMA Date: 2004-06-23 Impact factor: 56.272
Authors: Roxanne L Parrott; Kami J Silk; Megan R Dillow; Janice L Krieger; Tina M Harris; Celeste M Condit Journal: J Natl Med Assoc Date: 2005-07 Impact factor: 1.798
Authors: Cheryl L Thompson; Benjamin A Rybicki; Michael C Iannuzzi; Robert C Elston; Sudha K Iyengar; Courtney Gray-McGuire Journal: Am J Hum Genet Date: 2006-08-10 Impact factor: 11.025
Authors: Sarah Adelsperger; Cynthia A Prows; Melanie F Myers; Cassandra L Perry; Ariel Chandler; Ingrid A Holm; John A Lynch Journal: Health Commun Date: 2016-08-30